[1]何顺志,徐文芬.贵州中草药资源研究[M].贵阳:贵州科技出版社,2007.
[2]贵州省药品监督管理局.贵州省中药材、民族药材质量标准[S].北京:中国医药科技出版社,2020:36.
[3]刘慧,张庆捷,袁丽,等.苗药头花蓼研究进展[J].中国药业,2021,30(6):1-5.
[4]Ashraf M S,Gaur S,Bushen O Y,et al.Diagnosis,Treatment,and Prevention of Urinary Tract Infections in Post-Acute and Long-Term Care Settings:A Consensus Statement From AMDA's Infection Advisory Subcommittee[J].Journal of the American Medical Directors Association,2020,21(1):12-24.
[5]Collins L.Diagnosis and management of a urinary tract infection[J].British Journal of Nutrition,2019,28(2):84-88.
[6]Zhang H,Johnson A,Zhang G,et al.Susceptibilities of Gram-negative bacilli from hospital- and community-acquired intra-abdominal and urinary tract infections:a2016-2017 update of the Chinese SMART study[J].Infection and Drug Resistance,2019,12:905-914.
[7]AsadiKaram M R,Habibi M,Bouzari S.Urinary tract infection:Pathogenicity,antibiotic resistance and development of effective vaccines against Uropathogenic Escherichia coli [J].Molecular Immunology,2019,108:56-67.
[8]Khan A,Jhaveri R,Seed P C,et al.Update on Associated Risk Factors,Diagnosis,and Management of Recurrent Urinary Tract Infections in Children[J].Journal of the Pediatric Infectious Diseases Society,2019,8(2):152-159.
[9]Zhao F,Yang H,Bi D,et al.A systematic review and meta-analysis of antibiotic resistance patterns,and the correlation between biofilm formation with virulence factors in uropathogenic E.coli isolated from urinary tract infections [J].Microbial Pathogenesis,2020,1441(1):104196.
[10]Desai D,Goh K G K,Sullivan M J,et al.Hemolytic activity and biofilm-formation among clinical isolates of group B streptococcus causing acute urinary tract infection and asymptomatic bacteriuria[J].International Journal of Medical Microbiology,2021,311(6):151520.
[11]Chamoun M N,Sullivan M J,Goh K G K,et al.Restriction of chronic Escherichia coli urinary tract infection depends upon T cell-derived interleukin-17,a deficiency of which predisposes to flagella-driven bacterial persistence[J].FASEB Journal,2020,34(11):14572-14587.
[12]贵州省中医研究所.苗族医药学[M].贵阳:贵州民族出版社,1992:506.
[13]国家中医药管理局《中华本草》编委会.中华本草·苗药卷[M].贵阳:贵州科技出版社,2005:223-224.
[14]Song X,He Y,Liu M,et al.Mechanism underlying Polygonum capitatum effect on Helicobacter pylori-associated gastritis based on network pharmacology[J].Bioorganic Chemistry,2021,114:105044.
[15]Guan H,Li P,Wang Q,et al.Systematically Exploring the Chemical Ingredients and Absorbed Constituents of in Hyperuricemia Rat Plasma Using UHPLC-Q-Orbitrap HRMS[J].Molecules,2022,27(11):3521.
[16]周雯,张丽艳,谢立敏,等.超高效液相色谱-飞行时间质谱联用分析苗药头花蓼醇提物及水提物化学成分[J].中国中药杂志,2017,42(18):3557-3563.
[17]Li X,Yu M,Meng D,et al.A new chromone glycoside from Polygonum capitatum[J].Fitoterapia,2007,78(7-8):506-509.
[18]刘跃,胡杰,谢玉敏,等.UPLC-MRM-MS法测定头花蓼药材中7个指标成分[J].天然产物研究与开发,2015,27(1):73-76,88.
[19]唐丽,刘跃,郑林,等.热淋清颗粒中5个成分的UPLC-MS/MS法测定[J].中国医药工业杂志,2013,44(1):1029-1032.
[20]Liao S G,Zhang L J,Sun F,et al.Identification and characterisation of phenolics in Polygonum capitatum by ultrahigh-performance liquid chromatography with photodiode array detection and tandem mass spectrometry[J].Phytochemical Analysis,2013,24(6):556-568.
[21]吕炎唏,王隶书,程东岩,等.中药头花蓼的化学成分和药理作用研究概况[J].中国药师,2017,20(10):1849-1853.
[22]叶全知,黄光辉,黄豆豆,等.头花蓼中木脂素类降糖活性成分的研究[J].中药材,2017,40(1):107-110.
[23]赵焕新,白虹,李巍,等.头花蓼木脂素类化学成分研究[J].中药材,2010,(9):1409-1411.
[24]Zhang S,Huang J,Xie X,et al.Quercetin from Polygonum capitatum Protects against Gastric Inflammation and Apoptosis Associated with Helicobacter pylori Infection by Affecting the Levels of p38MAPK,BCL-2 and BAX[J].Molecules,2017,22(5):744.
[25]Zhang S,Mo F,Luo Z X,et al.Flavonoid Glycosides of Polygonum capitatum Protect against Inflammation Associated with Helicobacter pylori Infection[J].PLoS One,2015,10(5):126584.
[26]胡露,张锦,蔺良才,等.基于谱效关系的头花蓼抑菌作用物质基础研究[J].中药材,2016,39(9):2037-2040.
[27]Fan S,Huang Y,Zuo X,et al.Exploring the molecular mechanism of action of Polygonum capitatum Buch-Ham.ex D.Don for the treatment of bacterial prostatitis based on network pharmacology and experimental verification[J].Journal of Ethnopharmacology,2022,291:115007.
[28]Liao S G,Zhang L J,Sun F,et al.Antibacterial and anti-inflammatory effects of extracts and fractions from Polygonum capitatum[J].Journal of Ethnopharmacology,2011,134(3):1006-1009.
[29]王智谦.头花蓼中黄酮类化合物对大鼠血脂紊乱、肝损伤和动脉粥样硬化的保护[D].武汉:武汉大学,2018.
[30]Huang D,Du Z,Chen Y,et al.Bio-Guided Isolation of Two New Hypoglycemic Triterpenoid Saponins from Polygonum capitatum[J].Drug Design Development and Therapy,2021,15:5001-5010.
[31]刘伯宇,童南森,李雅雅,等.头花蓼提取物对2型糖尿病自发模型db/db小鼠的降糖机制研究[J].中国药学杂志,2017,52(5):384-390.
[32]沈冰冰,杨玉佩,Yasamin S,等.蓼科蓼属植物化学成分及生物活性分析(英文)[J].Digital Chinese Medicine,2018,1(1):19-36.
[33]国家药典委员会.中华人民共和国药典[S].北京:中国医药科技出版社,2020.
[34]李耿,郭宇博,李文姗,等.中药大品种科技竞争力报告(2019版)概要[J].中国现代中药,2020,22(1):1-20.
[35]Zhang K X,Wang Y S,Jing W G,et al.Improved quality control method for prescriptions of Polygonum capitatum through simultaneous determination of nine major constituents by HPLC coupled with triple quadruple mass spectrometry[J].Molecules,2013,18(10):11824-11835.
[36]Chen H,Yuan L,Ma X,et al.Herb-drug interaction:The effect of Polygonum capitatum extract on pharmacokinetics of levofloxacin in rats[J].J Pharmaceut Biomed,2021,195:113832.
[37]刘跃.头花蓼的口服吸收机制及其药代动力学研究[D].贵阳:贵阳医学院,2015.
[38]蒙文莎,袁丽,王朴,等.Caco-2细胞模型中头花蓼提取液对左氧氟沙星吸收的影响[J].中国药业,2022,31(8):37-42.
[39]Wang B,Lu Y,Wang R,et al.Transport and metabolic profiling studies of amentoflavone in Caco-2 cells by UHPLC-ESI-MS/MS and UHPLC-ESI-Q-TOF-MS/MS[J].J Pharmaceut Biomed,2020,189:113441.
[40]于连婷,矫艳磊,于美娜,等.Caco-2单层细胞模型在中药化学成分吸收转运研究中的应用[J].吉林医药学院学报,2022,43(1):50-52.
[41]Wang Q,Kuang Y,Song W,et al.Permeability through the Caco-2 cell monolayer of 42 bioactive compounds in the TCM formula Gegen-Qinlian Decoction by liquid chromatography tandem mass spectrometry analysis[J].J Pharmaceut Biomed,2017,146:206-213.
[42]Wang G,Hao R,Liu Y,et al.Tissue distribution,metabolism and absorption of Rhizoma Paridis Saponins in the rats[J].Journal of Ethnopharmacology,2021,273:114038.
[43]Saib S,Delavenne X.Inflammation Induces Changes in the Functional Expression of P-gp,BCRP,and MRP2:An Overview of Different Models and Consequences for Drug Disposition[J].Pharmaceutics,2021,13(10):1544.
[44]Rendic SP.Metabolism and interactions of Ivermectin with human cytochrome P450 enzymes and drug transporters,possible adverse and toxic effects[J].Archives of Toxicology,2021,95(5):1535-1546.
[45]张超,华悦,李喆,等.巴戟天中有效成分在Caco-2细胞模型中的吸收转运[J].中国现代中药,2022,24(5):837-844.
[46]陈宝婷,林爱华,陈举亮,等.芒果苷在Caco-2细胞上的摄取特性的LC-MS/MS法分析[J].时珍国医国药,2022,33(2):342-344.
[47]Leonard W,Xiong Y,Zhang P,et al.Enhanced Lignanamide Absorption and Antioxidative Effect of Extruded Hempseed(Cannabis sativa L.)Hull in Caco-2 Intestinal Cell Culture[J].Journal of Agricultural and Food Chemistry,2021,69(38):11259-11271.
[48]Wang Y,Ding X,Chen Y,et al.“Dialogue”between Caco-2 and DCs regulated by Ganoderma atrum polysaccharide in intestinal-like Caco-2/DCs co-culture model[J].Food Research International,2021,144:110310.
[49]刘跃,唐丽,曹旭,等.荭草提取物的肠外翻吸收研究[J].中国中药杂志,2014,39(11):2121-2125.
[50]Zheng L,Lu Y,Cao X,et al.Evaluation of the impact of Polygonum capitatum,a traditional Chinese herbal medicine,on rat hepatic cytochrome P450 enzymes by using a cocktail of probe drugs[J].Journal of Ethnopharmacology,2014,158:276-282.
[51]唐丽,刘跃,黄勇,等.离体外翻肠囊法研究头花蓼提取物中5个成分的肠吸收特性[J].中国药理学通报,2014,30(7):1031-1032.
[52]杨武,侯佳,陆苑,等.头花蓼提取物的大鼠在体肠吸收研究[J].中国中药杂志,2015,40(21):4281-4287.
[53]黄勇,唐丽,刘跃,等.野黄芩素在体肠吸收动力学研究[J].中国新药杂志,2014,23(4):457-461.
[54]郑林,唐丽,牟景丽,等.UPLC-MS法同时测定大鼠血浆中氧化芍药苷,没食子酸及咖啡酰基奎宁酸类成分[J].中成药,2014,36(5):937-941.
[55]Kuzma B A,Pence I J,Greenfield D A,et al.Visualizing and quantifying antimicrobial drug distribution in tissue[J].Advanced Drug Delivery Reviews,2021,177:113942.
[56]唐丽.贵州苗药头花蓼有效组分的体内外代谢研究[D].贵阳:贵阳医学院,2015.
[57]迟明艳,向文英,杨武,等.UPLC-Q-TOF/MS分析头花蓼提取物在大鼠尿液中的代谢产物[J].中国实验方剂学杂志,2016,22(17):77-80.
[58]向文英,梅朝叶,杨武,等.头花蓼的血清药物化学研究[J].中国药理学通报,2016,32(10):1476-1477.
[59]孙佳,梅朝叶,向文英,等.头花蓼有效组分在大鼠粪便和胆汁中的代谢研究[J].中草药,2016,47(18):3248-3254.